SCHEMBL25627478

SCHEMBL25627478

C#Cc1cc(C(C)(C)C)c(OCCN2CCOCC2)nc1N(C)C

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP2D6 P10635 2/20 0.43
▸ CYP3A4 P08684 1/20 0.43
▸ ACHE P22303 2/20 0.39
▸ BCHE P06276 1/20 0.39
▸ MAOA P21397 1/20 0.39
▸ MAOB P27338 1/20 0.39
▸ SIGMAR1 Q99720 2/20 0.38
▸ POLB P06746 1/20 0.37
▸ SYK P43405 1/20 0.37
▸ CNR2 P34972 1/20 0.37
▸ CYP1A2 P05177 1/20 0.36
▸ CYP2C19 P33261 1/20 0.36
▸ HSD17B10 Q99714 1/20 0.36
▸ NPC1 O15118 1/20 0.36
▸ KMT2A Q03164 3/20 0.36
▸ MEN1 O00255 2/20 0.36
▸ ALDH1A1 P00352 2/20 0.36
▸ SMN1; SMN2 Q16637 1/20 0.36
▸ LMNA P02545 1/20 0.36
▸ HIF1A Q16665 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25613068 0.72 CYP3A4 (0.45) CYP2D6CYP3A4ACHESIGMAR1POLB
SCHEMBL25625627 0.70 CYP3A4 (0.43) CYP2D6CYP3A4SIGMAR1POLBSYK
SCHEMBL25613066 0.70 CYP3A4 (0.46) CYP2D6CYP3A4ACHEMAOASIGMAR1
SCHEMBL25624610 0.69 CYP3A4 (0.42) CYP2D6CYP3A4SIGMAR1POLBSYK
SCHEMBL22962823 0.67 SYK (0.48) CYP2D6CYP3A4POLBSYKCNR2
SCHEMBL179256 0.67 CYP1A2 (0.76) CYP2D6POLBCYP1A2CYP2C19HSD17B10
SCHEMBL10224775 0.65 CYP3A4 (0.49) CYP2D6CYP3A4SIGMAR1POLBSYK
SCHEMBL24714753 0.65 GUCY1B2 (0.45) CYP2D6CYP3A4SIGMAR1POLBSYK
SCHEMBL14200213 0.64 KDM4E (0.56) CYP2D6CYP3A4SIGMAR1POLBSYK
SCHEMBL14200226 0.64 KDM4E (0.60) CYP2D6CYP3A4SIGMAR1POLBSYK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230159527-A1 COMPOUNDS AS BCL-2 INHIBITORS FOCHON BIOSCIENCES, LTD. (CN) 2023-05-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230159527-A1 COMPOUNDS AS BCL-2 INHIBITORS BCL2, BCL2L2, BCL2L1 CYP2D6 3553/4885CYP3A4 3544/4885ACHE 4703/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback